98%
921
2 minutes
20
Sharing genomic variant interpretations across laboratories promotes consistency in variant assertions. A landscape analysis of Australian clinical genetic-testing laboratories in 2017 identified that, despite the national-accreditation-body recommendations encouraging laboratories to submit genotypic data to clinical databases, fewer than 300 variants had been shared to the ClinVar public database. Consultations with Australian laboratories identified resource constraints limiting routine application of manual processes, consent issues, and differences in interpretation systems as barriers to sharing. This information was used to define key needs and solutions required to enable national sharing of variant interpretations. The Shariant platform, using both the GRCh37 and GRCh38 genome builds, was developed to enable ongoing sharing of variant interpretations and associated evidence between Australian clinical genetic-testing laboratories. Where possible, two-way automated sharing was implemented so that disruption to laboratory workflows would be minimized. Terms of use were developed through consultation and currently restrict access to Australian clinical genetic-testing laboratories. Shariant was designed to store and compare structured evidence, to promote and record resolution of inter-laboratory classification discrepancies, and to streamline the submission of variant assertions to ClinVar. As of December 2021, more than 14,000 largely prospectively curated variant records from 11 participating laboratories have been shared. Discrepant classifications have been identified for 11% (28/260) of variants submitted by more than one laboratory. We have demonstrated that co-design with clinical laboratories is vital to developing and implementing a national variant-interpretation sharing effort. This approach has improved inter-laboratory concordance and enabled opportunities to standardize interpretation practices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9674965 | PMC |
http://dx.doi.org/10.1016/j.ajhg.2022.10.006 | DOI Listing |
Allergy
September 2025
Allergy Immunology, Murdoch Children's Research Institute, Parkville, Australia.
Background: Uncertainty exists regarding the health-related quality of life (HRQL) benefits of food allergen oral immunotherapy (OIT). Up-to-date meta-analyses incorporating HRQL data from recent randomised trials are lacking.
Methods: Systematic searches of MEDLINE, Embase, CENTRAL and Google Scholar were conducted for food OIT randomised trials (versus any comparator) that measured HRQL with a validated instrument (27 July 2023).
Palliat Med Rep
May 2025
Palliative Care Outcomes Collaboration, University of Wollongong, Wollongong, Australia.
Background: The Palliative Care Outcomes Collaboration (PCOC), established in 2005 and funded by the Australian Government, is a national quality improvement initiative that integrates patient outcome measures into routine clinical practice. While PCOC supports services to improve patient care, implementation across diverse clinical settings presents challenges, with variation observed between similarly resourced services. Engaging services in continuous quality improvement proves difficult as the program grows.
View Article and Find Full Text PDFBMJ Open Sport Exerc Med
September 2025
School of Allied Health, Human Services and Sport, La Trobe University, Melbourne, Victoria, Australia.
Objectives: To evaluate the onset, frequency and time loss impact of recurrent calf muscle strain injuries in elite male Australian football players over a decade. To explore how outcomes are affected by alternative recurrence definitions.
Method: Calf muscle strain injuries were reported to the Soft Tissue Injury Registry of the Australian Football League (2014-2023).
Blood Vessel Thromb Hemost
August 2025
Northern Clinical Diagnostics and Thrombovascular Research, Northern Health, Melbourne, VIC, Australia.
Explor Res Clin Soc Pharm
December 2025
Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
Background: The emerging role of pharmacists in chronic kidney disease (CKD) care prompted the pharmacy-led screening and quality use of medicines in CKD trial (QUM-CKD), a pharmacy-led screening initiative to detect previously undiagnosed CKD and improve medication safety.Objective: To explore pharmacists' experiences and perspectives on the implementation of the QUM-CKD trial in Australian community pharmacies.
Methods: A descriptive phenomenological qualitative approach was employed, involving in-depth, semi-structured telephone interviews with thirteen metropolitan and rural community pharmacists in the trial.